Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Geron Corporation (NASDAQ:GERN), Allergan, Inc. (NYSE:AGN)
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) managed to keep its fall at -0.35% on above-normal volume of 1.74M shares. The stock settled at $111.01 after floating in a range of $110.39 to $112.81. Its latest price has reached market capitalization of $36.95 million. Its 52-week range has been $52.50 to $113.79. Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Has VRX Found The Bottom and Ready To Move Up? Find Out Here
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) traded up on a volume of 1.73 million, lower than its standard daily volume. Shares have gained 5.07% to $4.56. Over the last twelve months, the stock has gained 42.5% and faced a worst price of $2.07. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders.
For How Long AVNR’s Gloss will Attract Investors? Find out via this report
Geron Corporation (NASDAQ:GERN) settled 5.68% higher at $3.35 on below -normal volume of 1.72M shares during the last trading day. The stock has its 12-month high at $3.95 and 52-week low price was $0.91. It traded in a range of $3.15 to $3.38 during the last trading day. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Why Should Investors Buy GERN After the Recent Fall? Just Go Here and Find Out
In the last trading session, Allergan, Inc. (NYSE:AGN) was up on low volume, trading at a volume of 1.72M versus its average daily volume of 1.80 million shares. At $90.66, the stock has attained market capitalization of 26.91 billion. Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Will AGN Continue To Move Higher? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)